Successful Conversion Surgery in Advanced Hilar Cholangiocarcinoma Treated With Durvalumab Plus Gemcitabine and Cisplatin
- 29 April 2025
- journal article
- Published by SAGE Publications in The American Surgeon™
- Vol. 91 (7) , 1217-1220
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Conversion surgery for initially unresectable locally advanced biliary tract cancer: A multicenter collaborative study conducted in Japan and KoreaJournal of Hepato-Biliary-Pancreatic Sciences, 2024
- Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 studyThe Lancet Gastroenterology & Hepatology, 2024
- Perihilar Cholangiocarcinoma – Novel Benchmark Values for Surgical and Oncological Outcomes From 24 Expert CentersAnnals of Surgery, 2021
- Improvement in Perioperative and Long-term Outcome After Surgical Treatment of Hilar CholangiocarcinomaArchives of Surgery, 2012
- Management Strategies in Resection for Hilar CholangiocarcinomaAnnals of Surgery, 1992